Similarly, extracellular vesicle-PD-1 has shown potential as a dynamic biomarker of patient response to melanoma immunotherapy, though it remains in need of further clinical validation to confirm its effectiveness and practicality in routine settings [49]. The gene discussed is PDCD1; the disease is melanoma.